List view / Grid view
8 December 2015 | By Victoria White
New data, presented at AES 2015, show that Eisai's Fycompa (perampanel) treatment reduces primary and secondary generalised tonic clonic seizures and is well tolerated versus placebo...
7 December 2015 | By Victoria White
The data shows that a good proportion of people with partial-onset seizures, who have not responded when treated with carbamazepine, may respond to eslicarbazepine acetate...
16 October 2015 | By Victoria White
Phase II results show lenvatinib, when used in combination with everolimus, demonstrates significantly improved PFS versus everolimus alone in people with metastatic renal cell carcinoma...
13 October 2015 | By Victoria White
Five abstracts have highlighted the use of Eisai’s eribulin and lenvatinib in rare cancers at the German Association of Hematology and Oncology Meeting...
9 September 2015 | By Victoria White
Data presented at the International Epilepsy Congress in Istanbul show Eisai’s perampanel may significantly reduce seizure frequency, both in patients with primary generalised tonic-clonic (PGTC) seizures and partial epilepsy...
24 August 2015 | By Victoria White
Phase III study results for Eisai’s Fycompa® (perampanel) in primary generalised tonic-clonic (PGTC) seizures have been published for the first time...
31 July 2015 | By Victoria White
Eisai and Halozyme are to collaborate to evaluate Halaven in combination with PEGPH20 in first line HER2-negative metastatic breast cancer...
31 July 2015 | By Victoria White
Eisai has submitted regulatory applications in the US, EU and Japan for eribulin for the treatment of patients with inoperable soft tissue sarcoma (STS)...
29 July 2015 | By Victoria White
Eisai has received a Breakthrough Therapy designation for Lenvima for the potential indication of advanced and/or metastatic renal cell carcinoma...
8 July 2015 | By Victoria White
Eisai’s Fycompa (perampanel), a once-daily epilepsy treatment that inhibits AMPA receptors, launches in the United Kingdom today...
25 June 2015 | By Victoria White
The EC has granted marketing authorisation approval for perampanel for primary generalised tonic-clonic (PGTC) seizures in patients with epilepsy...
9 June 2015 | By Victoria White
Lenvima launches in the UK today as a treatment option for people with radioactive iodine refractory differentiated thyroid cancer (RAI refractory DTC)...
1 June 2015 | By Victoria White
The EC has approved Lenvima in the treatment of adult patients with progressive, locally advanced or metastatic differentiated thyroid carcinoma...
27 May 2015 | By Victoria White
Eisai has received a positive opinion from the EMA’s CHMP for the use of Fycompa for the adjunctive treatment of PGTC seizures...
26 May 2015 | By Victoria White
Data for anti-epileptic drug eslicarbazepine acetate shows it to be effective and well tolerated in elderly people with partial onset seizures (POS)...
